ClinicalTrials.gg
Not yet recruitingNCT07515651MIDAS-SBRTUpdated Sep 28, 2026

Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity

A Phase 2 interventional study of Image-guided Radiotherapy in Prostate Cancer (Adenocarcinoma), sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Prostatic Neoplasms by University Health Network, Toronto — 22 open to participants now, 28 under way, 2 of them phase 3. Prostatic Neoplasms · University Health Network, Toronto.

Planned enrollment
39th of 85
50 · median 48
Started
2026
with 3 others
Phase 2
29 of 101
7 open now
Primary completion
2034-10
later than 27 of 27 live
Registered
100th of 101
by date

Among the 101 studies in Prostatic Neoplasms by University Health Network, Toronto, this one is the 39th largest by planned enrollment of the 85 interventional ones that give a count, is one of 4 that started in 2026, is one of 29 in phase 2, reaches primary completion later than 27 of the 27 other live ones, and was the 100th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

22 of the 101 studies in Prostatic Neoplasms by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 22 open studies →

Where they have run

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Prostatic Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

This is a single arm trial that is recruiting a total of 50 participants that have been diagnosed with prostate bed (where the prostate was taken out) or regional (surrounding lymph nodes) recurrence of a prostate cancer following surgery. Salvage radiation treatment represents the main treatment option, with long-term cure rates on the order of 70%. Currently, salvage radiation treatment to the prostate bed and the pelvic lymph nodes is delivered using external beam radiation therapy (EBRT) in 20-33 sessions, over 4-6.5 weeks. Potential study participants have undergone a PSMA PET scan, which has found recurrent cancer in the prostate bed or lymph nodes. This study will investigate personalizing your radiation treatment based on this information. Participants on this study will receive lower than standard radiation dose to areas of the surgical site which do not show evidence of disease on the scan.

This personalized radiotherapy will be delivered in 5 treatments over two weeks, rather than the four to 6 weeks which is the current standard of care. Participants will have a routine history, blood collection for PSA and hormone levels, toxicity assessment, and EPIC-26 \& IPSS questionnaires at each follow-up visit. These will take place at 1, 3, 6, 12, 24, 36, and 60 months after radiation treatment.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old.
  • proven initial diagnosis of adenocarcinoma prostate cancer.
  • Radical prostatectomy > 6 months prior to commencing SBRT.
  • Biochemical relapse with local and/or regional recurrence proven with PSMA PET
  • 0-1.

Exclusion criteria

Exclusion Criteria:

  • Presence of para-aortic lymph nodes or distant .
  • Chronic pelvic inflammatory disease.
  • for radiation treatment.
  • Previous radiation treatment within the pelvis.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Molecular Imaging Informed Radiation Dose Escalation and De-escalation

    Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas.

    Radiation: Image-guided Radiotherapy

Interventions

  • RadiationImage-guided Radiotherapy

    * Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas with SBRT, 25Gy in 5 fractions to prostate bed +/- pelvic lymph nodes delivered every other day with a boost to PSMA avid disease of 35 Gy in 5 fraction * Treatment of pelvic lymph nodes and androgen deprivation therapy for 0-24 months at clinician discretion

06

What researchers measure

Primary outcomes

  1. Radiation-induced Acute Grade ≥2 Toxicity

    Acute (less than or equal to 90 days) toxicity will be evaluated by using prospective follow-up and grading according to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: Baseline to 5-year follow up

Secondary outcomes

  1. Acute and Late GI and GU toxicities

    Cumulative incidence function will be used to estimate the cumulative incidence of grade ≥2 GI and GU, graded per Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

    Time frame: Estimated at 6 months and 2 years following treatment

  2. Local Recurrence

    Cumulative incidence function with death as a competing risk will be used to estimate local recurrence

    Time frame: Estimated at 2 years and 5 years following treatment

  3. Biochemical Disease Free Survival

    Defined as survival until evidence of either biochemical progression (defined as a rise in prostate-specific antigen (PSA) ≥0.2ng/ml above the PSA nadir followed by a sequentially equal or higher value) following postoperative radiotherapy, clinical or radiological progression, initiation of non-protocol systemic therapy, or death from prostate cancer

    Time frame: Estimated at 2 years and 5 years following treatment

  4. Patient-reported quality-of-life assessed by EPIC-26 and IPSS

    Patient-Reported Quality of Life will be assessed at baseline and at each follow-up visit (1, 3, 6, 12, 18, 24, 36, 48, and 60 months) using the following assessment questionnaires: EPIC-26 and IPSS

    Time frame: Baseline to 5-year follow-up

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2034, 96 months later.

Of 610 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 86. This study's planned 96 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 28, 2026: start May 2026 → Oct 2026, primary completion May 2034 → Oct 2034 and completion May 2034 → Oct 2034.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 7, 2026
StartEst.
Oct 1, 2026was May 2026
Primary completionEst.
Oct 1, 2034was May 2034
CompletionEst.
Oct 1, 2034was May 2034
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 1, 2026→Oct 1, 2026
Sep 28, 2026
Primary completion
May 1, 2034→Oct 1, 2034
Sep 28, 2026
Study completion
May 1, 2034→Oct 1, 2034
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Start date May 1, 2026→Oct 1, 2026
    Primary completion May 1, 2034→Oct 1, 2034
    Study completion May 1, 2034→Oct 1, 2034
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07515651
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2034 (estimated)
Completion
Oct 1, 2034 (estimated)
Last update
Sep 28, 2026

Study contacts

Andrew McPartlin, MD
Contact
andrew.mcpartlin@uhn.ca
416-946-4501 ext. 4855

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion